ATE347557T1 - Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung - Google Patents
Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendungInfo
- Publication number
- ATE347557T1 ATE347557T1 AT01914191T AT01914191T ATE347557T1 AT E347557 T1 ATE347557 T1 AT E347557T1 AT 01914191 T AT01914191 T AT 01914191T AT 01914191 T AT01914191 T AT 01914191T AT E347557 T1 ATE347557 T1 AT E347557T1
- Authority
- AT
- Austria
- Prior art keywords
- fluorisoquinoline
- derivatives
- production
- pde
- copd
- Prior art date
Links
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000087121 | 2000-03-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE347557T1 true ATE347557T1 (de) | 2006-12-15 |
Family
ID=18603181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01914191T ATE347557T1 (de) | 2000-03-23 | 2001-03-22 | Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6924292B2 (de) |
| EP (1) | EP1270577B1 (de) |
| AT (1) | ATE347557T1 (de) |
| AU (1) | AU2001239550A1 (de) |
| CA (1) | CA2404226A1 (de) |
| DE (1) | DE60125026T2 (de) |
| WO (1) | WO2001070746A1 (de) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| DE10110772A1 (de) * | 2001-03-07 | 2002-09-12 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren |
| WO2003000697A1 (en) * | 2001-06-22 | 2003-01-03 | Takeda Chemical Industries, Ltd. | Furoisoquinoline derivative, process for producing the same, and use |
| GB0118373D0 (en) * | 2001-07-27 | 2001-09-19 | Glaxo Group Ltd | Novel therapeutic method |
| WO2003035650A1 (en) * | 2001-09-25 | 2003-05-01 | Takeda Chemical Industries, Ltd. | Entry inhibitor |
| AU2003281691A1 (en) * | 2002-07-26 | 2004-02-16 | Takeda Pharmaceutical Company Limited | Furoisoquinoline derivative and use thereof |
| AU2003263216A1 (en) * | 2002-08-17 | 2004-03-11 | Nycomed Gmbh | Benzonaphthyridines with PDE 3/4 inhibiting activity |
| CA2495597A1 (en) * | 2002-08-17 | 2004-03-04 | Altana Pharma Ag | Novel phenanthridines |
| AU2003263393A1 (en) * | 2002-09-04 | 2004-03-29 | Glenmark Pharmaceuticals Limited | New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| KR20050065624A (ko) | 2002-10-23 | 2005-06-29 | 그렌마크 파머수티칼스 엘티디. | 염증성 및 알레르기 질환의 치료에 유용한 신규한트리사이클릭 화합물, 이의 제조 방법 및 이를 함유하는약제 조성물 |
| SI1620429T1 (sl) | 2003-04-11 | 2009-08-31 | Glenmark Pharmaceuticals Sa | Nove heterociklične spojine, uporabne za zdravljenje vnetnih in alergijskih motenj: postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo |
| WO2004099170A2 (en) | 2003-04-30 | 2004-11-18 | The Institutes For Pharmaceutical Discovery, Llc | Phenyl substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b |
| US20050186276A1 (en) * | 2003-07-17 | 2005-08-25 | Pfizer Inc | Pharmaceutical formulations |
| WO2005023253A1 (en) | 2003-09-05 | 2005-03-17 | Altana Pharma Ag | Use of pde4 inhibitors for the treatment of diabetes mellitus |
| PL2589599T4 (pl) | 2004-03-03 | 2015-06-30 | Takeda Gmbh | Nowe hydroksy-6-heteroarylofenantrydyny i ich zastosowanie jako inhibitorów PDE4 |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| MX2007004400A (es) | 2004-10-13 | 2007-06-19 | Glenmark Pharmaceuticals Sa | Procedimiento para la preparacion de n-(3,5-dicloropirid-a-il)-4- ifluorometoxi-8-metanosulfonamido-dibenzo [b,d] difuran-1-carboxamida. |
| UA88795C2 (ru) | 2004-12-17 | 2009-11-25 | Гленмарк Фармасьютікалс С.А. | Гетероциклические соединения, которые применяются для лечения воспалителных и аллергических нарушений |
| PL1831227T3 (pl) | 2004-12-17 | 2013-10-31 | Glenmark Pharmaceuticals Sa | Nowe związki heterocykliczne użyteczne w leczeniu stanów zapalnych i dolegliwości alergicznych |
| ES2337083T3 (es) | 2005-03-02 | 2010-04-20 | Nycomed Gmbh | (2r,4ar,10br)-6-(2,6-dimetoxipiridin-3-il)-9-exoti-8-metoxi-1,2,3,4,4a,10b-hexahidrofenantridin-2-ol, sal de hc1. |
| CN102600144A (zh) | 2005-03-08 | 2012-07-25 | 奈科明有限责任公司 | 治疗糖尿病的罗氟司特 |
| CR9465A (es) | 2005-03-25 | 2008-06-19 | Surface Logix Inc | Compuestos mejorados farmacocineticamente |
| AP2007004244A0 (en) | 2005-05-10 | 2007-12-31 | Intermune Inc | Method of modulating stress-activated protein kinase system |
| EP2275096A3 (de) | 2005-08-26 | 2011-07-13 | Braincells, Inc. | Neurogenese durch modulation des Muscarinrezeptors |
| EP2258357A3 (de) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenese mit Acetylcholinesterasehemmer |
| US20070048389A1 (en) * | 2005-08-26 | 2007-03-01 | Fu-Pao Tsao | Stabilized and preserved ketotifen ophthalmic compositions |
| US20070048388A1 (en) * | 2005-08-26 | 2007-03-01 | Fu-Pao Tsao | Stabilized and preserved ketotifen ophthalmic compositions |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| EP2314289A1 (de) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba-rezeptor-vermittelte modulation von neurogenese |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
| EP2021000A2 (de) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenese mittels angiotensin-modulation |
| WO2008030651A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| CA2676173A1 (en) * | 2007-02-16 | 2008-08-28 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
| EP2100599A1 (de) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalationszusammensetzung enthaltend Aclidinium zur Behandlung von Asthma sowie chronisch-obstruktiver Lungenerkrankung |
| EP2100598A1 (de) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalationszusammensetzung enthaltend Aclidinium zur Behandlung von Asthma sowie chronisch-obstruktiver Lungenerkrankung |
| EP2296653B1 (de) | 2008-06-03 | 2016-01-27 | Intermune, Inc. | Verbindungen und verfahren zur behandlung von entzündungserkrankungen und fibrotischen erkrankungen |
| CN104784180A (zh) * | 2008-07-28 | 2015-07-22 | 武田药品工业株式会社 | 药物组合物 |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| EP2510928A1 (de) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium zur Verbesserung der Schlafqualität bei atemwegserkrankten Patienten |
| WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| RU2692485C2 (ru) | 2014-04-02 | 2019-06-25 | Интермьюн, Инк. | Противофиброзные пиридиноны |
| WO2018073110A1 (en) | 2016-10-20 | 2018-04-26 | Basf Se | Quinoline compounds as fungicides |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE756105A (fr) * | 1969-09-15 | 1971-03-15 | Geigy Ag J R | Nouveaux acides carboxyliques heterocycliques et medicaments contenant de tels acides |
| US4193926A (en) * | 1974-03-20 | 1980-03-18 | Schering Aktiengesellschaft | 4-(Polyalkoxy phenyl)-2-pyrrolidones |
| DE2413935A1 (de) * | 1974-03-20 | 1975-10-16 | Schering Ag | 4-(polyalkoxy-phenyl)-2-pyrrolidone |
| JPH07121933B2 (ja) * | 1988-03-28 | 1995-12-25 | キッセイ薬品工業株式会社 | ジヒドロベンゾフラノン誘導体 |
| GB9027055D0 (en) * | 1990-12-13 | 1991-02-06 | Sandoz Ltd | Organic compounds |
| US6153406A (en) * | 1993-07-23 | 2000-11-28 | North American Vaccine, Inc. | Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B |
| PT828728E (pt) * | 1995-05-18 | 2003-06-30 | Altana Pharma Ag | Di-hidrobenzofuranos de fenilo |
| US6763307B2 (en) * | 2000-03-06 | 2004-07-13 | Bioseek, Inc. | Patient classification |
-
2001
- 2001-03-22 AU AU2001239550A patent/AU2001239550A1/en not_active Abandoned
- 2001-03-22 AT AT01914191T patent/ATE347557T1/de not_active IP Right Cessation
- 2001-03-22 CA CA002404226A patent/CA2404226A1/en not_active Abandoned
- 2001-03-22 WO PCT/JP2001/002277 patent/WO2001070746A1/ja not_active Ceased
- 2001-03-22 US US10/239,439 patent/US6924292B2/en not_active Expired - Fee Related
- 2001-03-22 EP EP01914191A patent/EP1270577B1/de not_active Expired - Lifetime
- 2001-03-22 DE DE60125026T patent/DE60125026T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1270577A4 (de) | 2003-09-17 |
| WO2001070746A1 (en) | 2001-09-27 |
| DE60125026D1 (de) | 2007-01-18 |
| DE60125026T2 (de) | 2007-06-28 |
| US6924292B2 (en) | 2005-08-02 |
| CA2404226A1 (en) | 2001-09-27 |
| US20040092582A1 (en) | 2004-05-13 |
| EP1270577B1 (de) | 2006-12-06 |
| AU2001239550A1 (en) | 2001-10-03 |
| EP1270577A1 (de) | 2003-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1270577A4 (de) | Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung | |
| WO2004024728A3 (en) | Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors | |
| WO2004046112A3 (en) | 3-amino-piperidine derivatives and processes for their preparation | |
| IS6444A (is) | Pýrimidín karboxamíð nytsamleg sem latar á PDE4 samsætuensím | |
| NO20042378L (no) | A2B-adenosinreseptorantagonister | |
| WO2003093269A3 (de) | Substituierte pyrazolo-pyrimidin-4-one | |
| CY1106969T1 (el) | Αναστολεις dpp-iv | |
| NO20064577L (no) | Tetrahydronaftyndin-derivater nyttige som histamin H3 reseptorligander | |
| WO2007009656A3 (de) | Neues 1,4-benzothiazepin-1,1-dioxidderivat mit verbesserten eigenschaften, verfahren zu dessen herstellung, diese verbindung enthaltende arzneimittel und dessen verwendung | |
| WO2001090071A3 (de) | Substituierte iminoazine als herbizide | |
| WO2003011274A3 (en) | Use of a pde4 inhibitor in combination with an anticholinergic agent for the treatment of pulmonary disease such as asthma | |
| WO2006018718A3 (en) | Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors | |
| TW200500364A (en) | Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors | |
| WO2004020430A3 (fr) | Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique | |
| NO20055854L (no) | (2-hyroksy-2-(4-hydroksy-3-hydroksymetylfenyl)--etylamino)-propylfenylderivater som beta2 agonister | |
| WO2003041647A3 (en) | Synthesis and purification of valacyclovir | |
| WO2005033066A3 (fr) | Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique sanofi-synthelabo | |
| DE60204463D1 (de) | Substituierte 8-Arylchinoline als PDE4-Hemmer | |
| WO2004082629A3 (en) | Novel cyclosporins | |
| WO2004067703A3 (en) | 5ht7 antagonists and inverse agonists | |
| WO2004111008A3 (en) | Use of a compound of formula i for making a pharmaceutical composition | |
| EA200100906A1 (ru) | Композиция контролируемого высвобождения для лечения copd хронического обструктивного заболевания легких | |
| WO2007010356A8 (en) | Process for the preparation of sulfonamide derivatives | |
| WO2005079496A3 (en) | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity | |
| WO2003093278A3 (en) | Process for the preparation of ceftiofur acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |